- Home
- RA vs TNGX Comparison
RA vs TNGX Comparison
Compare RA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- TNGX
- Stock Information
- Founded
- RA 2016
- TNGX 2014
- Country
- RA United States
- TNGX United States
- Employees
- RA 1260
- TNGX N/A
- Industry
- RA Investment Managers
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- RA Finance
- TNGX Health Care
- Exchange
- RA Nasdaq
- TNGX Nasdaq
- Market Cap
- RA 711.7M
- TNGX 723.2M
- IPO Year
- RA N/A
- TNGX N/A
- Fundamental
- Price
- RA $13.45
- TNGX $7.58
- Analyst Decision
- RA
- TNGX Strong Buy
- Analyst Count
- RA 0
- TNGX 6
- Target Price
- RA N/A
- TNGX $10.00
- AVG Volume (30 Days)
- RA 280.8K
- TNGX 2.6M
- Earning Date
- RA 01-01-0001
- TNGX 11-05-2025
- Dividend Yield
- RA 14.73%
- TNGX N/A
- EPS Growth
- RA N/A
- TNGX N/A
- EPS
- RA N/A
- TNGX N/A
- Revenue
- RA N/A
- TNGX $24,296,000.00
- Revenue This Year
- RA N/A
- TNGX $20.42
- Revenue Next Year
- RA N/A
- TNGX N/A
- P/E Ratio
- RA N/A
- TNGX N/A
- Revenue Growth
- RA N/A
- TNGX N/A
- 52 Week Low
- RA $11.89
- TNGX $1.03
- 52 Week High
- RA $17.32
- TNGX $8.80
- Technical
- Relative Strength Index (RSI)
- RA 53.49
- TNGX 51.87
- Support Level
- RA $13.17
- TNGX $7.66
- Resistance Level
- RA $13.54
- TNGX $8.80
- Average True Range (ATR)
- RA 0.11
- TNGX 0.51
- MACD
- RA 0.01
- TNGX -0.04
- Stochastic Oscillator
- RA 75.68
- TNGX 33.70
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.